公开(公告)号：US20190153538A1

公开(公告)日：2019-05-23

申请号：US15766086

申请日：2016-10-08

Applicant: Oryzon Genomics, S.A.

Inventor： Wei-Yi CHENG ,  Mark D. DEMARIO ,  Fiona MACK ,  Francesca MILLETTI ,  William E. PIERCEALL

IPC: C12Q1/6886 ,  G16H50/30 ,  G16H50/20

Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with LSD1 inhibitors, said method comprising measuring mRNA expression levels of one or more genes selected from the list of ASCL1, DDC, CEACAM6, LRRIQ4, NR0B2, GRP, CEACAM5, SOX21, OR51E2, SEC11C, BAALC, CCDC40, RAB3B, RGS17, ABCE1, ETS2, CCDC154, SPAG6, PON1, TMEM176A, C1orf127, IGF2BP2, IGFBP5, FAM84A, FOXA2, HOXA10, NCAM1, NCAM2, NEUROD1, KRT8, ENO2, AVP, OXT, SYP, CHGA, CHGB, BCL2 and MYC.

公开(公告)号：US20190256929A1

公开(公告)日：2019-08-22

申请号：US16346909

申请日：2017-11-02

Applicant: ORYZON GENOMICS, S.A.

Inventor： Fabian BIRZELE ,  Wei-Yi CHENG ,  Mark D. DEMARIO ,  Fiona MACK ,  Francesca MILLETTI ,  William E. PIERCEALL

IPC: C12Q1/6886 ,  G16H50/20 ,  G01N33/50

Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) biomarkers in patients treated with Lysine Demethylase 1 (LSD 1) inhibitors and methods of determining the sensitivity of a cell to an LSD 1 inhibitor by measuring PD biomarkers.